CL2017002314A1 - Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes - Google Patents
Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentesInfo
- Publication number
- CL2017002314A1 CL2017002314A1 CL2017002314A CL2017002314A CL2017002314A1 CL 2017002314 A1 CL2017002314 A1 CL 2017002314A1 CL 2017002314 A CL2017002314 A CL 2017002314A CL 2017002314 A CL2017002314 A CL 2017002314A CL 2017002314 A1 CL2017002314 A1 CL 2017002314A1
- Authority
- CL
- Chile
- Prior art keywords
- polynucleotide
- salt
- composition
- methods
- multivalent cations
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title abstract 13
- 108091033319 polynucleotide Proteins 0.000 title abstract 13
- 239000002157 polynucleotide Substances 0.000 title abstract 13
- 150000003839 salts Chemical class 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 150000001768 cations Chemical class 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- -1 cation salt Chemical class 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151891P | 2015-04-23 | 2015-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002314A1 true CL2017002314A1 (es) | 2018-05-04 |
Family
ID=55911083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002314A CL2017002314A1 (es) | 2015-04-23 | 2017-09-13 | Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes |
Country Status (36)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42569B1 (fr) | 2015-04-23 | 2020-08-31 | Geron Corp | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP4060345A1 (en) | 2016-12-19 | 2022-09-21 | Ventana Medical Systems, Inc. | Peptide nucleic acid conjugates |
| US11866696B2 (en) * | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| JP7441455B2 (ja) * | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
| EP3727470B1 (en) | 2017-12-18 | 2024-11-20 | Ventana Medical Systems, Inc. | Peptide nucleic acid conjugates |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
| US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
| US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| DE69130333T2 (de) | 1990-08-31 | 1999-03-04 | Regents Of The University Of Minnesota, Minneapolis, Minn. | Harze für die Feststoff-Peptidsynthese |
| US5281701A (en) | 1991-07-12 | 1994-01-25 | Applied Biosystems, Inc. | Process and compounds for RNA synthesis |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| PL316434A1 (en) | 1994-03-18 | 1997-01-06 | Lynx Therapeutics | Oligonucleotidic phosphoramides n3'-p5', their compositions, synthesising and hydridising methods as well as immunological properties in respect to nuclease |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| AU733610B2 (en) | 1996-12-20 | 2001-05-17 | Geron Corporation | Methods for detecting and inhibiting the RNA component of telomerase |
| US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
| US6114519A (en) | 1997-10-15 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Synthesis of sulfurized oligonucleotides |
| US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
| AU767646B2 (en) | 1999-09-10 | 2003-11-20 | Geron Corporation | Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use |
| JP2002060341A (ja) | 2000-08-21 | 2002-02-26 | Terumo Corp | 止血剤 |
| WO2002077184A2 (en) | 2001-03-23 | 2002-10-03 | Geron Corporation | Oligonucleotide conjugates |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| JP4690324B2 (ja) | 2003-09-09 | 2011-06-01 | ジェロン・コーポレーション | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
| TW200540180A (en) | 2004-05-28 | 2005-12-16 | Sankyo Co | Telomerase inhibitor ena oligonucleotide |
| RS56361B1 (sr) | 2004-07-02 | 2017-12-29 | Geron Corp | Sinteza zaštićenih 3'-amino nukleozidnih monomera |
| CN101321877B (zh) * | 2005-10-03 | 2013-04-10 | 应用生物系统有限责任公司 | 用于扩增核酸的组合物、方法和试剂盒 |
| WO2008127305A2 (en) | 2006-11-01 | 2008-10-23 | Biogen Idec Ma Inc. | Method of isolating biomacromolecules using low ph and divalent cations |
| SI2605794T1 (sl) * | 2010-08-20 | 2017-01-31 | Replicor Inc. | Oligonukleotidni kelatni kompleksi |
| US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
| US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
| AR091065A1 (es) | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| ES2770638T3 (es) * | 2012-06-14 | 2020-07-02 | Life Technologies Corp | Nuevas composiciones, métodos y kits para la reacción en cadena de la polimerasa (PCR) |
| RS59363B1 (sr) | 2012-12-07 | 2019-11-29 | Geron Corp | Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| MA42569B1 (fr) | 2015-04-23 | 2020-08-31 | Geron Corp | Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent |
-
2016
- 2016-04-21 MA MA42569A patent/MA42569B1/fr unknown
- 2016-04-21 WO PCT/US2016/028657 patent/WO2016172346A1/en not_active Ceased
- 2016-04-21 AU AU2016250576A patent/AU2016250576C1/en active Active
- 2016-04-21 US US15/134,740 patent/US10745687B2/en active Active
- 2016-04-21 HR HRP20201218TT patent/HRP20201218T1/hr unknown
- 2016-04-21 RS RS20200935A patent/RS60645B1/sr unknown
- 2016-04-21 SI SI201630771T patent/SI3286203T1/sl unknown
- 2016-04-21 PT PT167206366T patent/PT3286203T/pt unknown
- 2016-04-21 PH PH1/2017/501927A patent/PH12017501927B1/en unknown
- 2016-04-21 SG SG11201707893RA patent/SG11201707893RA/en unknown
- 2016-04-21 TN TNP/2017/000411A patent/TN2017000411A1/en unknown
- 2016-04-21 DK DK16720636.6T patent/DK3286203T3/da active
- 2016-04-21 EP EP16720636.6A patent/EP3286203B1/en active Active
- 2016-04-21 CN CN201680014382.0A patent/CN107429247B/zh active Active
- 2016-04-21 JP JP2017548279A patent/JP2018513127A/ja not_active Withdrawn
- 2016-04-21 EA EA201791753A patent/EA035885B1/ru unknown
- 2016-04-21 MX MX2017011642A patent/MX383293B/es unknown
- 2016-04-21 ES ES16720636T patent/ES2798270T3/es active Active
- 2016-04-21 HU HUE16720636A patent/HUE051148T2/hu unknown
- 2016-04-21 BR BR112017019627-1A patent/BR112017019627B1/pt active IP Right Grant
- 2016-04-21 MD MDE20180204T patent/MD3286203T2/ro unknown
- 2016-04-21 LT LTEP16720636.6T patent/LT3286203T/lt unknown
- 2016-04-21 PE PE2022001164A patent/PE20221275A1/es unknown
- 2016-04-21 UA UAA201708890A patent/UA124521C2/uk unknown
- 2016-04-21 MA MA042157A patent/MA42157A/fr unknown
- 2016-04-21 ME MEP-2020-161A patent/ME03811B/me unknown
- 2016-04-21 KR KR1020177025835A patent/KR102401252B1/ko active Active
- 2016-04-21 SM SM20200389T patent/SMT202000389T1/it unknown
- 2016-04-21 PE PE2017001516A patent/PE20171785A1/es unknown
- 2016-04-21 CA CA2978191A patent/CA2978191C/en active Active
- 2016-04-21 CN CN202110878917.1A patent/CN113564168B/zh active Active
- 2016-04-21 MY MYPI2017703910A patent/MY187804A/en unknown
- 2016-04-21 SG SG10201909816P patent/SG10201909816PA/en unknown
- 2016-04-21 TW TW105112455A patent/TWI736532B/zh active
-
2017
- 2017-08-30 IL IL254222A patent/IL254222A0/en active IP Right Grant
- 2017-09-05 ZA ZA201706041A patent/ZA201706041B/en unknown
- 2017-09-12 CO CONC2017/0009217A patent/CO2017009217A2/es unknown
- 2017-09-13 CL CL2017002314A patent/CL2017002314A1/es unknown
- 2017-10-04 SA SA517390103A patent/SA517390103B1/ar unknown
-
2020
- 2020-07-09 CY CY20201100632T patent/CY1123197T1/el unknown
- 2020-07-10 US US16/926,340 patent/US11441144B2/en active Active
-
2021
- 2021-05-04 AU AU2021202803A patent/AU2021202803A1/en not_active Abandoned
- 2021-07-01 JP JP2021110090A patent/JP2021152079A/ja active Pending
-
2022
- 2022-09-02 JP JP2022140111A patent/JP2022168017A/ja not_active Withdrawn
-
2025
- 2025-01-27 JP JP2025011546A patent/JP2025061848A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002314A1 (es) | Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes | |
| CY1123932T1 (el) | Δομες πολυειδικου αντισωματος | |
| CO2017011957A2 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
| CL2016002010A1 (es) | Métodos y sistemas para generar mapas colaborativos compartidos | |
| MX2017015046A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| UY37340A (es) | Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas | |
| MX386500B (es) | Anticuerpos contra icos | |
| MX2018005551A (es) | Anticuerpos que se unen especificamente a pd-1, y sus usos. | |
| BR112014009066B8 (pt) | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica | |
| CL2018001770A1 (es) | Composiciones de decil mercaptanos mezclados y uso de las mismas como colectoras de productos químicos de minería | |
| AR110677A1 (es) | Anticuerpos anti-c1s y métodos para usarlos | |
| BR112017000135A2 (pt) | processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico | |
| MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
| BR112017015414A2 (pt) | máquina fresadora e método de aplicação da máquina fresadora | |
| BR112016015820A2 (pt) | Transformante para expressar cis-preniltransferase e receptor nogo b | |
| MX385237B (es) | Aleaciones magneticas de cobre. | |
| BR112017007411A2 (pt) | método em a máquina de plantio de mudas e máquina de plantio de mudas | |
| BR112016025196A2 (pt) | composições de oligonucleotídeo e métodos de fazê-las | |
| MX2017000023A (es) | Proceso para preparar fenilalcanos sustituidos. | |
| BR112019001409A2 (pt) | células renais bioativas para o tratamento de doença renal crônica | |
| BR112014015288A2 (pt) | máquina e processo para tornear pelo menos ressaltos planos de um eixo de manivela que circunda pinos de manivela | |
| DOP2015000294A (es) | Preparado farmacéutico | |
| BR112016024466A2 (pt) | método para a síntese de clofarabina | |
| CL2011000617A1 (es) | Celda electrolitica y proceso para la obtencion de metales mediante electrodialisis reactiva que comprende al menos una unidad basica con tres compartimentos de iguales dimensiones, separados por membranas de intercambio ionico, en donde dos de los compartimentos contendran el anolito y el otro el catolito. | |
| MX2020007702A (es) | Nanoemulsiones transparentes que comprenden aceite laurico. |